Literature DB >> 19602607

The variability in ultrafiltration achieved with icodextrin, possibly explained.

Daniele Venturoli1, Tarun K Jeloka, Fevzi F Ersoy, Bengt Rippe, Dimitrios G Oreopoulos.   

Abstract

BACKGROUND: A recent study by Jeloka et al. (Perit Dial Int 2006; 26:336-40) highlighted the high variability in maximum ultrafiltered volume (UF(max)) and the corresponding dwell time (t(max)) obtained using 7.5% icodextrin solution. We aimed to pinpoint the possible sources of this phenomenon by simulating the icodextrin ultrafiltration (UF) profiles according to the three-pore model of peritoneal transport.
METHOD: The individual UF time courses observed in the study by Jeloka et al. (n = 29) were first characterized by linear and quadratic regression. We were then able to identify four main patterns. These were then adapted to UF profiles generated by the three-pore model by systematically altering the values of some model parameters, namely, the mass transfer area coefficient (MTAC or PS) for icodextrin/glucose, the peritoneal UF coefficient (LpS), the plasma colloid osmotic pressure gradient (DeltaPi), and the macromolecular clearance out of the peritoneal cavity (Cl(LF)).
RESULTS: Modifications in the PS values caused only marginal variations in UF(max) and t(max), while more significant changes were produced by altering LpS and Cl(LF). However, far more evident was the importance of changes in DeltaPi. In fact, lowering DeltaPi to 14 mmHg caused a steady increase in UF with 10 - 14 hour dwells. On the contrary, the UF profiles became nearly "flat" when DeltaPi was increased to 30 mmHg. The parallel shifts induced by altering icodextrin metabolite concentrations did not markedly influence UF(max) or t(max).
CONCLUSION: The UF pattern in icodextrin dwells seem to be mainly determined by the plasma colloid osmotic pressure, while only moderate changes can be seen with alterations in LpS and Cl(LF). The result is not completely unexpected considering that icodextrin acts by inducing a strong colloid osmotic gradient. A number of clinical studies would be needed, however, in order to prove this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602607

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  6 in total

1.  Peritoneal residual volume induces variability of ultrafiltration with icodextrin.

Authors:  Alp Akonur; Clifford J Holmes; John K Leypoldt
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

2.  A New Method to Increase Ultrafiltration in Peritoneal Dialysis: Steady Concentration Peritoneal Dialysis.

Authors:  Vicente Pérez-Díaz; Alfonso Pérez-Escudero; Sandra Sanz-Ballesteros; Guadalupe Rodríguez-Portela; Susana Valenciano-Martínez; Sofía Palomo-Aparicio; Esther Hernández-García; Luisa Sánchez-García; Raquel Gordillo-Martín; Hortensia Marcos-Sánchez
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

3.  A patient with refractory nephrotic syndrome withdrawn from peritoneal dialysis.

Authors:  Satoshi Morimoto; Nobuyuki Takahashi; Kazunori Someya; Tatsuyori Morita; Fusakazu Jo; Nagaoki Toyoda; Atsushi Kosaki; Mitsushige Nishikawa; Toshiji Iwasaka
Journal:  Clin Exp Nephrol       Date:  2010-02-26       Impact factor: 2.801

4.  Low-Polydispersity Glucose Polymers as Osmotic Agents for Peritoneal Dialysis.

Authors:  John K Leypoldt; Catherine M Hoff; Alp Akonur; Clifford J Holmes
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

5.  Predicting the Peritoneal Absorption of Icodextrin in Rats and Humans Including the Effect of α-Amylase Activity in Dialysate.

Authors:  Alp Akonur; Clifford J Holmes; John K Leypoldt
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

6.  Long Peritoneal Dialysis Dwells With Icodextrin: Kinetics of Transperitoneal Fluid and Polyglucose Transport.

Authors:  Anna Olszowska; Jacek Waniewski; Joanna Stachowska-Pietka; Elvia Garcia-Lopez; Bengt Lindholm; Zofia Wańkowicz
Journal:  Front Physiol       Date:  2019-10-29       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.